Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 2793 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Abbasi J. First phase 1 trial of a prophylactic mRNA vaccine reported. JAMA 2017;318:2173. [Ref.ID 102169]
3. Cita con resumen
4. Cita con resumen
Anónimo. Semma Therapeutics raises $114 million for new diabetes treatment. DIA Daily 2017:1. [Ref.ID 102151]
5. Cita con resumen
6.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
7. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
8. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
9. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
10.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]
11. Cita con resumen
Okano A, Isley NA, Boger DL. Peripheral modifications of [?[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics. Proceedings of the National Academy of Sciences of the United States of America 2017:13 de marzo. [Ref.ID 101615]
12.
Anónimo. Brivaracetam for epilepsy. Australian Prescriber 2017;40:112-3. [Ref.ID 101611]
13. Cita con resumen
Anónimo. Mepolizumab. Australian Prescriber 2017;40:35-6. [Ref.ID 101502]
14. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
16. Cita con resumen
Anónimo. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017;59:22-3. [Ref.ID 101421]
17. Cita con resumen
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;37:429-39. [Ref.ID 101410]
18. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
19. Cita con resumen
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, de Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. [Ref.ID 101392]
20. Cita con resumen
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, for the OPERA I and OPERA II Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34. [Ref.ID 101375]
Seleccionar todas
 
 1 a 20 de 2793 siguiente >>